Abstract Number: 1994 • 2016 ACR/ARHP Annual Meeting
Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis
Background/Purpose: While the impact of interstitial lung disease (ILD) on mortality in RA has been demonstrated, less is known about the influence of other lung…Abstract Number: 1995 • 2016 ACR/ARHP Annual Meeting
Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Background/Purpose: Smoking is well recognized as a risk factor for rheumatoid arthritis (RA), and determinant of RA disease activity, severity, response to therapy, and possibly…Abstract Number: 1997 • 2016 ACR/ARHP Annual Meeting
Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
Background/Purpose: According to national guidelines issued in 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish patients…Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting
Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab
Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…Abstract Number: 1999 • 2016 ACR/ARHP Annual Meeting
Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting
Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting
Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections
Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…Abstract Number: 2002 • 2016 ACR/ARHP Annual Meeting
Differences in Features of Chronic Back Pain in First Degree Relatives of Patients with Ankylosing Spondylitis (AS) Compared to the U.S. Population
Background/Purpose: To compare the clinical features of spondyloarthritis in first degree relatives (FDRs) of patients with ankylosing spondylitis (AS) with chronic back pain (CBP) with…Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…Abstract Number: 2004 • 2016 ACR/ARHP Annual Meeting
Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Background/Purpose: Disease activity has an important impact on work productivity in patients with Ankylosing Spondylitis (AS). However, if and to what extent this is the…Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting
Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting
Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…Abstract Number: 2007 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis
Background/Purpose: Making the diagnosis of axial spondyloarthritis (axSpA) may be difficult. Antibodies against CD74 have been shown to be present in 2/3 of patients…Abstract Number: 2008 • 2016 ACR/ARHP Annual Meeting
Rapamycin Elicits Rapid and Lasting Improvement of Disease Activity through Blocking Pro-Inflammatory T Cell Lineage Specification in Patients with Active SLE
Background/Purpose: The rationale for this prospective, biomarker-driven, open-label clinical trial of rapamycin (ClinicalTrials.gov Identifier: NCT00779194) has been based on growing evidence for involvement of the…Abstract Number: 2009 • 2016 ACR/ARHP Annual Meeting
The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures
Background/Purpose: The Phase IIb MUSE study (NCT01438489) of intravenous anifrolumab in 305 patients with moderate to severely active SLE (300 or 1,000 mg vs. placebo,…
ACR Meeting Abstracts